Terumo Corporation

4543.T · Tokyo Stock Exchange · JPY

2.513,00JPY

+2,00 (+0,08 %)Stand 11. Nov., 6:21

Vortag 2.511,00

Kennzahlen

Eröffnung
2.519,50
Vortag
2.511,00
Tagesspanne
2.502,00 – 2.583,50
52 Wochen
1.900,00 – 2.689,00
Volumen
2,95 Mio.
Ø Volumen
5,2 Mio.
Börsenwert
3,71 Bio. ¥
KGV
–
Gewinn je Aktie (TTM)
111,49
Dividendenrendite
–
Beta
0,2
Nächste Zahlen
–

Finanzen

JPYFY 2026FY 2025FY 2024FY 2023FY 2022
Umsatz1,13 Bio.1,04 Bio.921,86 Mrd.820,21 Mrd.703,3 Mrd.
Herstellungskosten537,2 Mrd.503,39 Mrd.467,69 Mrd.426,37 Mrd.354,56 Mrd.
Bruttogewinn594,68 Mrd.532,78 Mrd.454,17 Mrd.393,84 Mrd.348,75 Mrd.
Forschung und Entwicklung074,22 Mrd.69,06 Mrd.61,58 Mrd.51,84 Mrd.
Vertrieb und Verwaltung409,94 Mrd.279,53 Mrd.250,92 Mrd.214,92 Mrd.178,79 Mrd.
Operatives Ergebnis184,74 Mrd.179,02 Mrd.134,2 Mrd.117,33 Mrd.118,12 Mrd.
EBITDA276,92 Mrd.242,51 Mrd.219,66 Mrd.188,44 Mrd.174,58 Mrd.
Nettogewinn135,91 Mrd.116,98 Mrd.106,37 Mrd.89,33 Mrd.88,81 Mrd.
Gewinn je Aktie (verwässert)92,1278,9971,4759,4858,69

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.

CEO
Hikaru Samejima
Mitarbeitende
31.185
Hauptsitz
Tokyo, TY, JP
Sektor
Healthcare
Branche
Medical - Devices
Börsengang
20. Juni 1982
Website
terumo.com

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.